Drug Trial News

RSS

NIH-funded clinical trial aims to restore vision in people who have lost vision due to IIH

In an NIH-funded clinical trial, led at Saint Louis University by professor of ophthalmology Sophia Chung, M.D., researchers aim to bring sight back to those who have lost vision due to idiopathic intracranial hypertension.

29 Sep 2014

Oral afatinib significantly improves progression-free survival in patients with head and neck cancer

The tyrosine kinase inhibitor afatinib significantly improved progression-free survival compared to methotrexate in patients with recurrent or metastatic squamous cell carcinoma of the head and neck after failure of platinum-based chemotherapy, the results of a phase III trial show.

29 Sep 2014

Anamorelin drug safe and well tolerated in advanced non-small cell lung cancer, Phase III trial reveals

A new drug, anamorelin, improves appetite and body mass in patients with advanced lung cancer who are suffering cancer anorexia and cachexia, according to phase III data presented at the ESMO 2014 Congress in Madrid, Spain.

29 Sep 2014

Phase III trial: Rolapitant lessens chemotherapy-induced nausea and vomiting

Rolapitant reduces nausea and vomiting in patients receiving cisplatin-based chemotherapy, according to the results of a phase III trial presented for the first time today at the ESMO 2014 Congress in Madrid, Spain.

29 Sep 2014

Crizotinib drug effectively halts growth of ROS1-positive lung tumors

Treatment with the targeted therapy drug crizotinib effectively halts the growth of lung tumors driven by rearrangements of the ROS1 gene. In an article receiving Online First publication in the New England Journal of Medicine to coincide with a presentation at the European Society for Medical Oncology meeting, an international research team reports that crizotinib treatment led to significant tumor shrinkage in 36 of 50 study participants and suppressed tumor growth in another 9.

29 Sep 2014

MicroBiome Therapeutics' NM 505 drug can improve tolerability of metformin

MicroBiome TherapeuticsTM LLC, today reported positive topline results from a proof of concept study testing whether its investigational drug, NM 505, can improve the tolerability of metformin, the first-line therapy for Type 2 diabetes worldwide.

26 Sep 2014

Helsinn to present Phase III trial data of anamorelin at ESMO Congress

Helsinn Group, a company focused on building quality cancer care, today announces that Phase III data from the largest trial program of its kind to date in anamorelin, a novel, once-daily ghrelin receptor agonist in development for cancer-anorexia-cachexia (CACS) in non-small cell lung cancer will be presented at the 38th European Society for Medical Oncology Congress in Madrid, Spain, in 2014.

25 Sep 2014

NCCN ORP awards four research grants to advance development of nintedanib

The National Comprehensive Cancer Network Oncology Research Program has awarded four grants to investigators to evaluate and define the clinical effectiveness of the investigational compound nintedanib (BIBF 1120) in non-small cell lung, colorectal, and gastrointestinal cancers.

25 Sep 2014

Inovio, GeneOne to advance DNA-based Ebola vaccine into phase I clinical trial

Inovio Pharmaceuticals, Inc. announced it will advance its DNA vaccine for Ebola into a phase I clinical trial in a collaboration with GeneOne Life Science Inc., an international DNA vaccine manufacturer in which Inovio holds a minority interest.

24 Sep 2014

KemPharm to initiate clinical trials in Canada for lead product candidate KP201

KemPharm, Inc., a clinical-stage specialty pharmaceutical company engaged in the discovery and development of proprietary new molecular entity (NME) prodrugs, announced today that it received a No Objection Letter (NOL) from Health Canada to begin clinical trials in Canada for its lead product candidate KP201 (benzhydrocodone hydrochloride and acetaminophen)

23 Sep 2014

Elusys completes phase 3 clinical program of obiltoxaximab in healthy adult volunteers

Elusys Therapeutics, Inc., a biopharmaceutical company developing antibody therapies to treat infectious disease, today announced it has completed three phase 3 healthy adult volunteer safety studies of obiltoxaximab (ETI-204).

23 Sep 2014

TauRx achieves target enrolment in second LMTX Phase III clinical trial for Alzheimer's disease

TauRx Therapeutics Ltd has achieved its target enrolment of 700 subjects with mild Alzheimer's disease into the second of its two Phase III clinical trials of LMTX, a tau aggregation inhibitor, for the treatment of Alzheimer's disease.

22 Sep 2014

Phase IIa clinical trial data of ATL1102 in MS patients published in journal Neurology

Antisense Therapeutics is pleased to report the publication of previously generated Phase IIa clinical trial data on ATL1102 in the medical journal Neurology.

22 Sep 2014

Regulus begins ATHENA study to monitor changes in renal function in Alport syndrome patients

Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today it has initiated its ATHENA natural history of disease study in patients with Alport syndrome, a life-threatening genetic kidney disease with no approved therapy.

19 Sep 2014

Immune begins bertilimumab Phase II clinical trial for treatment of ulcerative colitis

Immune Pharmaceuticals Inc. announces today that it has initiated the screening of patients for a Phase II proof of concept clinical trial exploring the safety and efficacy of bertilimumab in the treatment of ulcerative colitis (UC).

18 Sep 2014

First data from phase 3 study of investigational once-weekly DPP-4 inhibitor for type 2 diabetes presented by MSD

MSD, known as Merck & Co., Inc. (NYSE: MRK) in the United States and Canada, today announced the presentation of the first data from the Phase 3 clinical development programme for omarigliptin, MSD’s investigational treatment for type 2 diabetes.

18 Sep 2014

Isis receives $4 million in milestone payment from Achaogen for initiation of plazomicin Phase 3 study

Isis Pharmaceuticals, Inc. announced that it has earned a $4 million milestone payment from Achaogen, Inc. associated with the initiation of a Phase 3 study of plazomicin in patients with serious multi-drug resistant (MDR), gram-negative bacterial infections.

17 Sep 2014

Radiation and endocrine therapy combination may not be necessary for all HR+ breast cancer patients

Treatment with endocrine therapy and radiation therapy as part of breast conservation is the current standard of care for women with hormone-receptor positive (HR+) invasive breast cancer. A new study by researchers at Fox Chase Cancer Center, however, shows that combination may not be necessary for all patient populations with the disease.

17 Sep 2014

UCSD researchers launch phase 1 trial to assess novel monoclonal antibody for CLL patients

Researchers at the University of California, San Diego School of Medicine have launched a phase 1 human clinical trial to assess the safety and efficacy of a new monoclonal antibody for patients with chronic lymphocytic leukemia (CLL), the most common form of blood cancer in adults.

17 Sep 2014

Cancer-fighting cocktail shows promising results for advanced cervical cancer

Combining a standard chemotherapy drug with a second drug that stops cells from dividing improves both the survival and response rates for those with advanced cervical cancer, a new study by UT Southwestern Medical Center cancer researchers finds.

16 Sep 2014

Drug Trial News

NIH-funded clinical trial aims to restore vision in people who have lost vision due to IIH

Oral afatinib significantly improves progression-free survival in patients with head and neck cancer

Anamorelin drug safe and well tolerated in advanced non-small cell lung cancer, Phase III trial reveals

Phase III trial: Rolapitant lessens chemotherapy-induced nausea and vomiting

Crizotinib drug effectively halts growth of ROS1-positive lung tumors

MicroBiome Therapeutics' NM 505 drug can improve tolerability of metformin

Helsinn to present Phase III trial data of anamorelin at ESMO Congress

NCCN ORP awards four research grants to advance development of nintedanib

Inovio, GeneOne to advance DNA-based Ebola vaccine into phase I clinical trial

KemPharm to initiate clinical trials in Canada for lead product candidate KP201

Elusys completes phase 3 clinical program of obiltoxaximab in healthy adult volunteers

TauRx achieves target enrolment in second LMTX Phase III clinical trial for Alzheimer's disease

Phase IIa clinical trial data of ATL1102 in MS patients published in journal Neurology

Regulus begins ATHENA study to monitor changes in renal function in Alport syndrome patients

Immune begins bertilimumab Phase II clinical trial for treatment of ulcerative colitis

First data from phase 3 study of investigational once-weekly DPP-4 inhibitor for type 2 diabetes presented by MSD

Isis receives $4 million in milestone payment from Achaogen for initiation of plazomicin Phase 3 study

Radiation and endocrine therapy combination may not be necessary for all HR+ breast cancer patients

UCSD researchers launch phase 1 trial to assess novel monoclonal antibody for CLL patients

Cancer-fighting cocktail shows promising results for advanced cervical cancer

Exploring the nanoscale: How AFM is transforming cosmetic science

Innovating Texture and Culture in Plant-Based Foods

Advancing brain microphysiological systems (bMPS)

Latest News